UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Items
On January 26, 2024, NightHawk Biosciences, Inc. (the “Company”) announced that it has determined to effectuate the change of the name of the Company to Scorpius Holdings, Inc. on February 6, 2024. In connection with the name change, the Company’s ticker will change to SCPX.
The Company is changing the name of the Company to Scorpius Holdings, Inc., to better reflect the Company’s successful shift into a pure-play, large molecule biomanufacturing CDMO. The Company will continue to operate its CDMO within the Scorpius BioManufacturing, Inc. subsidiary.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits. | |||
Exhibit Number |
Description | |||
104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 26, 2024 | NightHawk Biosciences, Inc. | |
By: | /s/ Jeff Wolf | |
Name: | Jeff Wolf | |
Title: | Chief Executive Officer |
Cover |
Jan. 26, 2024 |
---|---|
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 26, 2024 |
Entity File Number | 001-35994 |
Entity Registrant Name | NightHawk Biosciences, Inc. |
Entity Central Index Key | 0001476963 |
Entity Tax Identification Number | 26-2844103 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 627 Davis Drive |
Entity Address, Address Line Two | Suite 300 |
Entity Address, City or Town | Morrisville |
Entity Address, State or Province | NC |
Entity Address, Postal Zip Code | 27560 |
City Area Code | (919) |
Local Phone Number | 240-7133 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Common Stock [Member] | |
Common Stock | Common Stock, $0.0002 par value per share |
Trading Symbol | NHWK |
Security Exchange Name | NYSEAMER |
Common Stock Purchase Rights [Member] | |
Common Stock | Common Stock Purchase Rights |
Trading Symbol | None |
Security Exchange Name | NYSEAMER |